Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Nov 09, 2021 9:42am
178 Views
Post# 34104193

RE:Ga letter!!!

RE:Ga letter!!!


"I know I said I was working on lots of new releases and I have, but unfortunately we are still awaiting approval of many NRs by our partners (distributors, hospitals and alliances).  We will get them out as soon as we get permission."


banderas1976 wrote: Dear Friend; 

 
Attached is today’s news release.

Some background:

1. Concurrent with the release of the VMS+3.0, the Company re-started manufacturing its products (VMS+2.0 was made by a contract manufacturer).  This reduced costs and gave us more control.
2. Consequently, the Company now undergoes routine inspections to verify its ability to manufacture quality medical devices.  Medical devices have special requirements.
3. The Company has undergone quarterly inspections and passed them all with no significant non-conformities and so it has been moved to semi-annual inspections for its excellent performance.
4. As you will read in the NR, the Company passed our most recent semi-annual inspection and is authorized to continue to sell into Canada and USA.  Europe has different inspections and FYI, we are in compliance there as well.
5. While we routinely pass these inspections, it takes a concerted effort to maintain processes and updated them as regulations change (and they change often).
 
I know I said I was working on lots of new releases and I have, but unfortunately we are still awaiting approval of many NRs by our partners (distributors, hospitals and alliances).  We will get them out as soon as we get permission.
 
Thanks for the continued support and interest as we complete our mission to improve cardiac diagnostics worldwide for everyone and especially for children.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
519-803-6937
 



<< Previous
Bullboard Posts
Next >>